Skip to main content
. 2024 Jun 14;63(6):857–869. doi: 10.1007/s40262-024-01379-y

Fig. 1.

Fig. 1

Schematic representation of the FDA cabozantinib POPPK model for cabozantinib [13] (Ka1 = absorption rate constant from depot 1, Ka2 = absorption rate constant from depot 2, ALAG1 = lag time of depot 1, ALAG2 = lag time of depot 2, CL/F = apparent plasma clearance, Q/F = apparent distribution rate constant between compartments)